PHRX — Pharmadrug Share Price
0.000.00%
Last trade - 00:00- CA$1.08m
- CA$2.53m
- 29
- 30
- 11
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.68 | 0.01 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also operates through SecureDose Synthetics Inc., which is a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 6th, 2011
- Public Since
- August 16th, 2018
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 107,734,380
- Address
- 77 King St. West, Suite 2905, TORONTO, M5K 1H1
- Web
- https://pharmadrug.ca/
- Phone
- +1 6472021824
- Auditors
- CLEARHOUSE LLP
Upcoming Events for PHRX
Q2 2025 Pharmadrug Inc Earnings Release
Q3 2025 Pharmadrug Inc Earnings Release
Similar to PHRX
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
Asia Green Biotechnology
Canadian Securities Exchange
FAQ
What is the Pharmadrug share price?
As of Today at 22:37 UTC, shares in Pharmadrug are trading at CA$0.01. This share price information is delayed by 15 minutes.
How has the Pharmadrug share price performed this year?
Shares in Pharmadrug last closed at CA$0.01 and the price had moved by -71.43% over the past 365 days. In terms of relative price strength the Pharmadrug share price has underperformed the Toronto Stock Exchange 300 Composite Index by -75.29% over the past year.
What are the analyst and broker recommendations for Pharmadrug?
There is no consensus recommendation for this security.
Find out moreWhat is the Pharmadrug dividend yield?
Pharmadrug does not currently pay a dividend.
Does Pharmadrug pay a dividend?
Pharmadrug does not currently pay a dividend.
When does Pharmadrug next pay dividends?
Pharmadrug does not currently pay a dividend.
How do I buy Pharmadrug shares?
To buy shares in Pharmadrug you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmadrug?
As of the previous close price of CA$0.01, shares in Pharmadrug had a market capitalisation of CA$1.08m.
Where are Pharmadrug shares listed?
Here are the trading details for Pharmadrug:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: PHRX
What kind of share is Pharmadrug?
Based on an overall assessment of its quality, value and momentum Pharmadrug is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmadrug share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Pharmadrug share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmadrug. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -35.89%.
As of the last closing price of CA$0.01, shares in Pharmadrug were trading -37.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmadrug PE Ratio?
The Pharmadrug PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmadrug?
We do not have data on Pharmadrug's directors